Health Industry

Latest California Healthline Stories

Newsom’s $12 Billion Medicaid Makeover Banks on Nonprofits’ Buy-In

California’s Medicaid program is relying heavily on community groups to deliver new social services to vulnerable patients, such as security deposits for homeless people and air purifiers for asthma patients. But many of these nonprofits face staffing and billing challenges and haven’t been able to deliver services effectively.

FDA Said It Never Inspected Dental Lab That Made Controversial AGGA Device

Johns Dental Laboratories stopped making the Anterior Growth Guidance Appliance last year after a KFF Health News-CBS News investigation into allegations of patient harm. The company had “never” reported any complaints about its products to the FDA, according to the agency.

KFF Health News' 'What the Health?': Newly Minted Doctors Are Avoiding Abortion Ban States

For the second year in a row, medical school graduates across specialties are shying away from applying for residency training in states with abortion bans or significant restrictions, according to a new study. Meanwhile, Medicare’s trustees report that the program will be able to pay its bills longer than expected — which could discourage Congress from acting to address the program’s long-term financial woes. Lauren Weber of The Washington Post, Joanne Kenen of the Johns Hopkins University schools of nursing and public health and Politico Magazine, and Anna Edney of Bloomberg News join KFF Health News’ Julie Rovner to discuss these stories and more.

Biden Team’s Tightrope: Reining In Rogue Obamacare Agents Without Slowing Enrollment

Federal regulators face a growing challenge — how to prevent rogue health insurance agents from switching unknowing consumers’ Obamacare coverage without making the enrollment process so cumbersome that enrollment declines.

Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge

The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.